Phase 2 Trial: Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response via Modulation of Androgen Receptor (SPIDERMAN)
/0 Comments/in Clinical Trial, Metastatic, Phase 2/by MaxPhase 1: AMG 509 (Xaluritamig) for Metastatic Hormone Sensitive Prostate Cancer
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1: Lartesertib and Tuvusertib Target DNA Repair to Fight Resistant Tumors
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxDecipher Test Emerges as Key Predictor for Chemotherapy Benefit in Metastatic Prostate Cancer
/0 Comments/in Retrospective studies/by MaxPlant Virus-Based Cancer Immunotherapy: A New Frontier in Fighting Cancer
/0 Comments/in Oncolytic, Preclinical Research/by MaxPSA Level at 6 Months as a Predictor of Long-Term Outcomes: Real 10-Year Overall Survival Data from the CHAARTED Trial
/0 Comments/in Post-hoc/by MaxNewsletter 34/2025
/0 Comments/in Newsletter/by MaxLAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hi fellow warriors! This time, I welcome you with a picture of the Milky Way. August may still be a slow month, but there is always something new to discover. Stay strong and fight on! As usual, we also have a podcast […]
Alpha DaRT: A Promising Frontier in the Treatment of Prostate, Bladder, and Advanced Cancers
/0 Comments/in Clinical Trial, Localized, Metastatic/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
225Ac abiraterone acetate ADC AI ai in healthcare alphafold antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T clinical trial clinical trials crispr darolutamide drug repurposing drug resistance enzalutamide HRR immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer olaparib oncolytic virus PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STAMPEDE trial theranostics
Latest Posts
- Newsletter 37/2025 September 14, 2025
- OST-504: A Novel Immunotherapy Targeting Prostate Cancer September 13, 2025
- Memantine Shows Promise Against Advanced Prostate Cancer September 11, 2025
- Pasritamig in Late-Line Prostate Cancer: From Early Findings to the KLK2-comPAS Trial September 11, 2025